Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B van der Meer

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
The Journal of Clinical Investigation|March 1, 1995
180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosaM F Jonkman, M C de Jong, K Heeres, et al.
Epilepsia|March 18, 2021
First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acidPim B van der Meer, Linda Dirven, Marta Fiocco, et al.
Rheumatology (Oxford, England)|April 6, 2007
Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosisE R Popa, C A Stegeman, W H Abdulahad, et al.
Neurology|February 8, 2023
Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort StudyPim B van der Meer, Linda Dirven, Marta Fiocco, et al.
Journal of Neuro-Oncology|July 1, 2021
The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamideMark P van Opijnen, Pim B van der Meer, Linda Dirven, et al.
Journal of Neuro-Oncology|April 18, 2018
Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapyPim B van der Meer, Esther J J Habets, Ruud G Wiggenraad, et al.
Neuro-Oncology Practice|January 8, 2025
Symptom management in isocitrate dehydrogenase mutant gliomaTobias Walbert, Edward K Avila, Florien W Boele, et al.
Journal of Neuro-Oncology|September 27, 2023
Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational studyPim B van der Meer, Linda Dirven, Marta Fiocco, et al.
Journal of Neurosurgery|October 1, 2021
Long-term health-related quality of life and neurocognitive functioning after treatment in skull base meningioma patientsFleur L Fisher, Amir H Zamanipoor Najafabadi, Pim B van der Meer, et al.
Neurology|April 29, 2025
Long-Term Follow-Up Results of Antiseizure Medication Withdrawal in Grade 2 and 3 Glioma Patients: A Prospective Observational StudyPim B van der Meer, Melissa Kerkhof, Linda Dirven, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
The Journal of Clinical Investigation|March 1, 1995
180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosaM F Jonkman, M C de Jong, K Heeres, et al.
Epilepsia|March 18, 2021
First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acidPim B van der Meer, Linda Dirven, Marta Fiocco, et al.
Rheumatology (Oxford, England)|April 6, 2007
Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosisE R Popa, C A Stegeman, W H Abdulahad, et al.
Neurology|February 8, 2023
Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort StudyPim B van der Meer, Linda Dirven, Marta Fiocco, et al.
Journal of Neuro-Oncology|July 1, 2021
The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamideMark P van Opijnen, Pim B van der Meer, Linda Dirven, et al.
Journal of Neuro-Oncology|April 18, 2018
Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapyPim B van der Meer, Esther J J Habets, Ruud G Wiggenraad, et al.
Neuro-Oncology Practice|January 8, 2025
Symptom management in isocitrate dehydrogenase mutant gliomaTobias Walbert, Edward K Avila, Florien W Boele, et al.
Journal of Neuro-Oncology|September 27, 2023
Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational studyPim B van der Meer, Linda Dirven, Marta Fiocco, et al.
Journal of Neurosurgery|October 1, 2021
Long-term health-related quality of life and neurocognitive functioning after treatment in skull base meningioma patientsFleur L Fisher, Amir H Zamanipoor Najafabadi, Pim B van der Meer, et al.
Neurology|April 29, 2025
Long-Term Follow-Up Results of Antiseizure Medication Withdrawal in Grade 2 and 3 Glioma Patients: A Prospective Observational StudyPim B van der Meer, Melissa Kerkhof, Linda Dirven, et al.
Pageof 14